Imitex is the only company targeting MEF2 – the master regulator of exercise-responsive genes that synergistically enhance both muscle metabolism and muscle mass. Imitex’s team has 20 years’ experience with this target, which was recently validated by the US NIH’s Molecular Transducers of Physical Activity (MoTrPAC) Consortium.
Imitex’s quantum computing drug discovery platform delivers faster, cheaper development with a focus on safety screening.
Imitex’s small molecule exercise mimetics target a significant and rapidly growing market, driven by the unprecedented global use of GLP-1 therapeutics, where 25-40% of weight lost is lean mass (muscle). Combined with sarcopenia, genetic disorders and cachexia this is a $45B market opportunity.
During exercise, MEF2 transcription factors activate genes that maintain muscle mass, boost metabolism, and enhance endurance. Imitex’s small molecules mimic this natural process, and have been developed and enhanced through several iterations of drug design, most recently through the application of iterative quantum-based artificial intelligence drug development models.
Imitex is the only company targeting MEF2 – and has 20 years’ experience with this target – a target which was recently validated by the US NIH’s Molecular Transducers of Physical Activity (MoTrPAC) Consortium.
Imitex is building on a strong foundation of research and drug development with a suite of new AI tools, and has identified a number of novel leads which it is progressing through optimization and non-clinical testing. The team’s networks and deep understanding of the value drivers in drug development mean that every decision in the development path is made with an eye to future partnering.
ScienceImitex was founded by a team of experienced scientists and biotechnology executives.
With deep scientific insight, proven commercial expertise, strong industry and government connections and access to world leading AI based drug development technology our founding team has positioned Imitex at the forefront of an emerging therapeutic segment.
Imitex is primed for growth, with the right technologies, expertise and networks to successfully develop first-in-class MEF2 activators for muscle preservation.
OUR TEAM
